Tougher Comps, New Capacity Online—Growth Still On Track
After a record Q1, Himadri faces a stiffer YoY baseline in Q2. The payoff: Anthraquinone Phase 1 ramps in-quarter, signalling the start of its ₹2,000 Cr expansion story. Street coverage is sparse and mixed.
The Setup
Himadri rode record commodity cycles and margin tailwinds into Q1—consolidated revenue of ₹1,432 Cr (+28% YoY) with EBITDA of ₹313 Cr at a 22% margin. That bar is now high. Q2 will face tougher YoY comps and seasonal dynamics typical of the quarter. But the narrative turns: Anthraquinone and Carbazole Phase 1 (capacity 2,600 MTPA) is expected to ramp in Q2, marking the start of the company's ₹2,000 Cr, multi-year expansion capex cycle. The real print will show whether it can hold margins through the ramp—and whether volumes offset any commodity headwinds.
~₹1,350–1,400 Cr
Q1 was ₹1,432 Cr; Q2 comps are stiffer; modest growth expected
~₹300–310 Cr
21–22% margin assumed; dependent on commodity prices & volume mix
~₹210–230 Cr
Tracking towards FY28 ₹1,100 Cr guidance; 23–25% growth expected
Phase 1 commissioning
Volume contribution likely modest in Q2; margin accretion will roll forward through H2
A strong print will show revenue in the ₹1,400+ Cr range with EBITDA margin sustained above 21%, early commentary on Anthraquinone ramp utilization, and any guidance lift on the capex deployment or volume trajectory into Q3–Q4. A weak print would flag commodity margin compression, lower-than-expected sequential volume, or revised capex pacing due to execution headwinds.
On Track?
Himadri is tracking its FY28 PAT guidance of ₹1,100 Cr—a 23% leap from FY26's ₹895 Cr—and Q1's 28% revenue growth suggests the run-rate is intact. Q2 will be a test of margin stability through a capacity ramp and seasonal transition. If the company holds EBITDA margin near 21% or better and volumes recover post-Anthraquinone commissioning, it stays on the long-term growth story. No delivery P&L has been found in the database for prior guidance verification, so the call rests on this quarter's evidence and the trajectory.
What the Street Says
Since Last Quarter—The Filings Scan
Routine capex & governance: Board approved ₹128 Cr for Anthraquinone/Carbazole Phase 2 (5,300 MTPA). Commercial paper issuance (₹150 Cr, issued Jul 9, redeemed Oct 7) signals normal working-capital management. Trading window closure from Oct 1 is standard pre-result protocol.
Strategic moves: Demerger of DBRL's tyre business approved by board (Sep 21). This simplifies the portfolio but adds execution complexity and regulatory steps through FY27; flag for ongoing updates. Sicona Battery investment (AUD 16.94 Lac additional tranche, Aug 25) shows ongoing venture-capital optionality. Subsidiary Sturdy Niketan stake divestment (34%, Sep 24) is a non-core realignment.
Awards & ownership: Golden Peacock Sustainability Award (Oct 8) is a positive brand marker. FII share rose to 6.80% from 6.80% Q1 FY27 (vs 5.98% in Q4 FY26), signalling gradual foreign interest. Promoter stake stable at 52.50%; no insider sales noted in bulk deals. VT Capital Market and NK Securities activity in bulk deals (May–Aug) are routine market-making.
1 · Anthraquinone Ramp & Utilization
Has Phase 1 been commissioned? What is implied utilization, and what is guidance for Phase 2 capex timeline? Any commentary on pricing or offtake for the new capacity will shape the multi-year narrative.
2 · Margin Stability
EBITDA margin at 21%+ or a miss? Watch management commentary on commodity input costs (especially oil-linked), realized pricing, and mix. A margin hold signals pricing power; a drop flags demand/cost headwinds.
3 · FY27 Guidance & Capex Deployment
Will the company reaffirm full-year growth targets or raise them? Any revision to the ₹2,000 Cr capex schedule? Q2 is the inflection for capital intensity—delays or cost overruns would be material flags.
Himadri's Q2 is the inflection from margin tailwinds to capacity growth. Record Q1 momentum, a new production line, and ₹2,000 Cr capex ahead set a compelling multi-year frame—but thin Street coverage and stiffer comparables mean the print must earn credibility. Watch margin hold, Anthraquinone utilization, and FY27 guidance reaffirmation. If execution is on-plan, a further re-rating is plausible; missteps on capex or margin could invite profit-taking off the recent highs.